Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Treatment Paradigms in AMD Management

By: Carl Regillo, MD; W. Lloyd Clark, MD

This course has expired. You can still review the content but course credit is no longer available.

Webinar Credits: 1

The increasing number of new patients with CNV and neovascular AMD presenting to retina specialists on top of the already large and active treatment population has created a desire among clinicians to reduce treatment burden. Recent studies suggest that long-term treatment outcomes are not necessarily sustained over time. This could be a result of under treatment, disease progression, or even tachyphylaxis to the anti-VEGF drug.

Until more is known about how neovascular AMD progresses and what the best treatment algorithms are, retina specialists will need to stay abreast of the latest study findings in order to continue to deliver the best patient care.

Expiration Date: Thursday, May 31, 2018
Release Date: May 2017

Learning Objectives

Upon completion of this activity, participants will be better able to:

  • Discuss the outcomes of pivotal studies in AMD, and how study results may differ from “real-world” dosing method
  • Identify patient subtypes (eg. RAP lesion, pigment epithelial detachments, occult lesions) that will require long-term treatment and imaging evaluation.
  • Develop a long term treatment plan for patients with AMD based on results from clinical trials and extension studies
  • Compare the extended safety outcomes of anti-VEGF therapies as published in long term studies.

Accreditation and Designation Statement

Accreditation and Designation Statement

ACCREDITATION STATEMENT

Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT

Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

The following faculty members have the following financial relationships with commercial interests:
•Lloyd Clark, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Bayer Pharmaceuticals; Genentech, Inc; Ohr Pharmaceutical, Inc.; Regeneron Pharmaceuticals, Inc.; and Santen Pharmaceutical Co., Ltd. Grant/Research Support: Allergan, Inc.; Genentech, Inc and Regeneron Pharmaceuticals, Inc.

•Carl Regillo, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan, Inc.; Genentech, Inc; Iconic Therapeutics; and Notal Vision. Grant/Research Support: Alcon; Allergan, Inc.; Genentech, Inc; GlaxoSmithKline; Iconic Therapeutics; Novartis; and Regeneron Pharmaceuticals, Inc.

Editorial Support Disclosure
•Cheryl Cavanaugh, MS, Evolve Medical Education LLC and Michelle Dalton, Writer; have no real or apparent conflicts of interest to report.
•Rishi P. Singh, MD, Peer Reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan Plc; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.

Video Resources

BackNext